Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P51003

UPID:
PAPOA_HUMAN

ALTERNATIVE NAMES:
Polynucleotide adenylyltransferase alpha

ALTERNATIVE UPACC:
P51003; Q86SX4; Q86TV0; Q8IYF5; Q9BVU2

BACKGROUND:
Poly(A) polymerase alpha, known for its alternative name Polynucleotide adenylyltransferase alpha, is integral in mRNA synthesis, specifically in adding the 3'-poly(A) tail. This process is vital for mRNA stability and efficient translation, with specificity achieved through interactions with CPSF at the enzyme's C-terminus.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Poly(A) polymerase alpha offers a pathway to innovative therapeutic approaches. Its critical role in gene expression regulation presents a unique opportunity for disease intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.